Biomarker Profiling in Abdominal Aortic Aneurysm Patients

Abdominal Aortic Aneurysm Clinical Trial

— BIOMArCS-AAA  

Official title:

Study of Biomarker Profiling to Unravel the Intertwined Pathophysiology of Coronary Artery Disease and Abdominal Aortic Aneurysm

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03703947
• Other study ID #: MEC-2017-019
• Status: Recruiting
• Start date: March 23, 2017
• Est. completion date: August 2024

Study information

• Verified date: March 2022
• Source: Erasmus Medical Center
• Contact: Isabella Kardys, MD, PhD
• Phone: +31650032051
• Email: i.kardys[@]erasmusmc.nl
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The BIOMArCS-AAA study aims to investigate the associations of (temporal patterns of) blood biomarkers with aneurysm growth in patients with abdominal aortic aneurysm (AAA), with particular attention to biomarkers that have demonstrated prognostic value for adverse disease outcomes in coronary artery disease and biomarkers for the main genetic pathways associated with AAA.

Description:

BIOMArCS-AAA is an observational, multicenter study. Patients with an abdominal aortic aneurysm (AAA) will be recruited through the vascular surgery outpatient clinic of Erasmus MC and Maasstad Ziekenhuis, the Netherlands. The prospective, longitudinal part of the study will include an arm with 120 AAA watchful waiting patients and an arm with 120 AAA patients undergoing endovascular aneurysm repair (EVAR), both with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, at 1 month after EVAR and at 6, 12, 18 and 24 months for all patients. CT will be conducted at baseline and 12 and 24 months, plus at 1 month in the EVAR patients. Quality of life and depression questionnaires will be performed at baseline, at 12 and 24 months of follow-up in all patients, and at 1 month only in EVAR patients. Additionally, a cross-sectional study will be performed in 200 patients treated for AAA with EVAR in the past years. In these patients, clinical data collection, blood sampling, ultrasound and CT will be performed at their next regular outpatient clinic visit.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 440
• Est. completion date: August 2024
• Est. primary completion date: August 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age of 18 years or older
• Capable of understanding and signing informed consent AND one of the following

1. Diagnosis of AAA, with a diameter =40mm, based on any imaging technique and treated by watchful waiting strategy (Prospective longitudinal study, Arm 1 watchful waiting group)

2. Planned to undergo EVAR for AAA (Prospective longitudinal study, Arm 2 EVAR group)

3. Underwent EVAR for AAA in past years (Cross-sectional study)

Exclusion Criteria:

• Patients with isolated iliac artery aneurysm, traumatic aneurysm, anastomotic aneurysm and infectious aneurysm
• Patients with a clinical diagnosed thoracic aneurysm (i.e. located in the chest, above the diaphragm)
• Coexistent condition with life expectancy = 1 year
• Dialysis dependent, (end stage) renal disease patients
• Women of childbearing age
• Linguistic barrier
• Unlikely to appear at all scheduled follow-up visits

Related Conditions & MeSH terms

• Abdominal Aortic Aneurysm
• Aneurysm
• Aortic Aneurysm
• Aortic Aneurysm, Abdominal

Locations

Country	Name	City	State
Netherlands	Erasmus Medical Center	Rotterdam	Zuid-Holland
Netherlands	Maasstad Ziekenhuis	Rotterdam	Zuid-Holland

Sponsors (2)

Lead Sponsor	Collaborator
Erasmus Medical Center	Maasstad Hospital

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Volume of the aneurysm sac	The primary study endpoint is volume of the aneurysm sac. This will be measured cross-sectionally, as well as repeatedly in the longitudinal part of the study by CT scan imaging during 24 months of follow-up.	Measured cross-sectionally, as well as repeatedly in the longitudinal part of the study by CT scan imaging during 24 months of follow-up.
Secondary	Maximal diameter of the aneurysm	Maximal diameter of the aneurysm by CT scan imaging	Measured cross-sectionally, as well as repeatedly in the longitudinal part of the study during 24 months of follow-up.
Secondary	Number of deceased patients due to all-cause mortality	All-cause mortality	During 24 months of follow-up in the longitudinal part of the study.
Secondary	Number of AAA-related adverse events in watchful waiting group	AAA related death, AAA rupture, or any AAA-related intervention.	During 24 months of follow-up in the watchful-waiting patients of the longitudinal part of the study.
Secondary	Number of AAA-related adverse events in EVAR patients	Endoleaks, migration >10 mm, device integrity failure, AAA-related death, late postimplantation AAA rupture, or any AAA-related secondary intervention.	During 24 months of follow-up in the EVAR patients of the longitudinal part of the study.
Secondary	Number of patients with cardiovascular events	Cardiovascular events: i.e. cardiovascular death, myocardial infarction, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG).	Cross-sectionally and during 24 months of follow-up in the longitudinal part of the study.
Secondary	Quality of life measured according to the EuroQol questionnaire	The validated questionnaire EuroQol will be used to assess health related quality of life	Measured repeatedly during 24 months of follow-up in the longitudinal part of the study.
Secondary	Depression measured according to the Hospital Anxiety and Depression Scale questionnaire	The Hospital Anxiety and Depression Scale (HADS) will be assessed to adjust for depression and anxiety in combination with the 2-item Patient Health Questionnaire (PHQ-2).	Measured repeatedly during 24 months of follow-up in the longitudinal part of the study.